FindTrial
Sign In

PB

DRUG2 trials

Sponsors

Mayo Clinic, Regeneron Pharmaceuticals

Conditions

Acquired Nephrogenic Diabetes InsipidusAutosomal Dominant Polycystic Kidney DiseaseCongenital Nephrogenic Diabetes InsipidusNephrogenic Diabetes InsipidusSepsis-Induced Hypotension

Phase 2

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
CompletedNCT05190744
Mayo ClinicAcquired Nephrogenic Diabetes Insipidus, Autosomal Dominant Polycystic Kidney Disease, Congenital Nephrogenic Diabetes Insipidus +1
Start: 2022-09-01End: 2025-12-08Updated: 2026-01-27
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
CompletedNCT06608901
Regeneron PharmaceuticalsSepsis-Induced Hypotension
Start: 2025-05-05End: 2026-04-28Updated: 2026-05-20